Aleksandra K Olow (Aleksandra Olow)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 4

Top Topics

Induced Pluripotent Stem Cells

Metastatic Breast Cancer

Top Venues

Nature chemistry

Journal of immunology (Baltimore, Md. : 1950)

Organic & biomolecular chemistry

Merck Research Laboratories

University of Amsterdam (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Merck Research Laboratories Nov 17 2019

United States

Associate Principal Scientist :: Oncology Genomics & Analytics, Genetics and Pharmacogenomics

Amgen Jul 21 2016 - Nov 17 2019

United States

Specialist Data Scientist :: Research Informatics

University of California San Francisco Oct 15 2015 - Jul 25 2016

United States

Postdoctoral Scholar :: Laboratory Medicine

Education History

University of Amsterdam Oct 10 2010 - Nov 25 2015

Netherlands

PHD :: Oncology

Universiteit Utrecht Sep 01 2009 - Jan 31 2012

Netherlands

MSC :: Biomedical Sciences

Publications

Yu Kawamata, Keun Ah Ryu, Gary N Hermann, Alexander Sandahl, Julien C Vantourout, Aleksandra K Olow, La-Tonya A Adams, Eva Rivera-Chao, Lee R Roberts, Samer Gnaim, Molhm Nassir, Rob C Oslund, Olugbeminiyi O Fadeyi, Phil S Baran
An electroaffinity labelling platform for chemoproteomic-based target identification. Nature chemistry (2023)
Tyler J Bechtel, Jayde M Bertoch, Aleksandra K Olow, Margaret Duich, Cory H White, Tamara Reyes-Robles, Olugbeminiyi O Fadeyi, Rob C Oslund
Proteomic mapping of intercellular synaptic environments via flavin-dependent photoredox catalysis. Organic & biomolecular chemistry (2022)
Aleksandra K Olow, Laura van 't Veer, Denise M Wolf
Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments. BMC cancer 21 (1) (2021)
Aeryon Kim, Chia-Jung Han, Ian Driver, Aleksandra K Olow, Andrew K Sewell, Zemin Zhang, Wenjun Ouyang, Jackson G Egen, Xin Yu
LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells. Journal of immunology (Baltimore, Md. : 1950) 203 (4) (2019)